08 Jan 2014, BioSpectrum Bureau , BioSpectrum
Singapore: Genzyme, which is a subsidiary of Sanofi, agreed to pay $22.30 million to settle a whistleblower lawsuit that accused the company of off-label marketing of its Seprafilm surgical product.
Seprafilm protects organs and muscles following surgery, forming a barrier that prevents them from attaching to one another during healing. The product has had FDA approval since 1996 for use during open surgeries, but whistleblowers claimed that Genzyme marketed the product for use during laparoscopic surgery.
Sales representatives working in Genzyme allegedly encouraged doctors to mix the product into liquid form and to inject it into the body.